Combination Products

Intercenter Consultative/Collaborative Review Process

On July 31, 2002, FDA issued an internal document (SMG 4101) to provide the policies and procedures for FDA staff to follow when requesting, receiving, handling, processing, and tracking formal consultative and collaborative reviews of combination products, devices, drugs and biologics. The objectives are to improve intercenter communication on combination products, as well as the timeliness and consistency of intercenter consultative and collaborative reviews. The document describes key policies regarding the consultative/collaborative review process, as well as responsibilities and procedures to be followed by those requesting and conducting intercenter reviews. The first revision of this document, effective February 14, 2003, implements interim measures to provide for the tracking of consultative and collaborative reviews of combination products by the Office of Combination Products. The document will continue to be refined and updated.


Page Last Updated: 10/15/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English